Cantor Fitzgerald analyst Rick Bienkowski initiated coverage of Editas Medicine with an Overweight rating and $15 price target. The analyst believes the shares are well positioned to rally in the coming year due to favorable intellectual property positioning and expected clinical data updates. Follow-up data from the Phase 1 Ruby study in sickle cell disease in mid-2023 could strengthen clinical proof of concept for EDIT-301, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EDIT:
- Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
- Shoreline to acquire Editas’ iNK cell franchise, related gene editing tech
- Editas Medicine provides update, to reduce headcount by approximately 20%
- Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
- Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
